Literature DB >> 1761069

Diurnal variation of methotrexate disposition in children with acute leukaemia.

G Ferrazzini1, H Sohl, I Robieux, D Johnson, E Giesbrecht, G Koren.   

Abstract

There is recent evidence that survival is improved when maintenance therapy for acute lymphocytic leukaemia in children is given at night. We have examined the possibility that diurnal variation in methotrexate pharmacokinetics may contribute to this improvement. In 6 children with leukaemia there was a significant fall in methotrexate plasma clearance at night (from 5.6 to 4.7 ml.kg-1.min-1). Renal clearance of methotrexate tended to fall at night and unbound renal clearance fell significantly (from 17.5 to 8.5 ml.min-1.kg-1 P less than 0.05). Creatinine clearance did not exhibit diurnal variation, whereas there was a significant fall in the non-glomerular clearance of methotrexate (from 14.8 to 6 ml.min-1.kg-1). Since methotrexate is a weak organic acid, its tubular secretion depends on urinary pH. At night urinary pH is more acidic, and this may result in more reabsorption and hence reduced renal clearance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761069     DOI: 10.1007/BF00626363

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia.

Authors:  G Ferrazzini; J Klein; H Sulh; D Chung; E Griesbrecht; G Koren
Journal:  J Pediatr       Date:  1990-11       Impact factor: 4.406

2.  Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?

Authors:  F M Balis; S L Jeffries; B Lange; R F Murphy; K M Doherty; C A Arndt; N Luery; D G Poplack
Journal:  Am J Pediatr Hematol Oncol       Date:  1989

3.  Circadian variations in presumably healthy men under conditions of peace time army reserve unit training.

Authors:  E L Kanabrocki; L E Scheving; F Halberg; R L Brewer; T J Bird
Journal:  Space Life Sci       Date:  1973-04

4.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

5.  Pharmacokinetic case for giving 6-mercaptopurine maintenance doses at night.

Authors:  A M Langevin; G Koren; S J Soldin; M Greenberg
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

6.  Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.

Authors:  G Koren; A M Langevin; N Olivieri; E Giesbrecht; A Zipursky; M Greenberg
Journal:  Am J Dis Child       Date:  1990-10

7.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

8.  Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening.

Authors:  G E Rivard; C Infante-Rivard; C Hoyoux; J Champagne
Journal:  Lancet       Date:  1985-12-07       Impact factor: 79.321

9.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; S Kuhn; S Chaudhary; S Feldman; M Verzosa; R J Aur; C Pratt; S L George
Journal:  N Engl J Med       Date:  1977-12-29       Impact factor: 91.245

10.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

Authors:  W E Evans; W R Crom; M Abromowitch; R Dodge; A T Look; W P Bowman; S L George; C H Pui
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

View more
  1 in total

1.  The Daily Expression of ABCC4 at the BCSFB Affects the Transport of Its Substrate Methotrexate.

Authors:  André Furtado; Rafael Mineiro; Ana Catarina Duarte; Isabel Gonçalves; Cecília R Santos; Telma Quintela
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.